Zobrazeno 1 - 10
of 260
pro vyhledávání: '"Julie R, Park"'
Autor:
Elizabeth Sokol, Brian LaBarre, Navin Pinto, Susan Kreissman, M. Meaghan Granger, Julie R. Park, Rochelle Bagatell, Arlene Naranjo, Steven G. DuBois
Publikováno v:
EJC Paediatric Oncology, Vol 4, Iss , Pp 100193- (2024)
Background: Response to induction chemotherapy has been shown to predict outcome in patients with high-risk neuroblastoma (HR-NB), with those achieving a complete response (CR) having superior outcomes. Methods: We evaluated whether conventional prog
Externí odkaz:
https://doaj.org/article/35ed301de8104030a4de7e354f8f16f4
Autor:
Esther R. Berko, Gabriela M. Witek, Smita Matkar, Zaritza O. Petrova, Megan A. Wu, Courtney M. Smith, Alex Daniels, Joshua Kalna, Annie Kennedy, Ivan Gostuski, Colleen Casey, Kateryna Krytska, Mark Gerelus, Dean Pavlick, Susan Ghazarian, Julie R. Park, Araz Marachelian, John M. Maris, Kelly C. Goldsmith, Ravi Radhakrishnan, Mark A. Lemmon, Yaël P. Mossé
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as the only mutated oncogene tractable for targeted therapy in neuroblastoma. Cells with these mutations respond to lorlatinib in pre-clinical studies, provid
Externí odkaz:
https://doaj.org/article/c0e4bcb6136d4cc7a5072df22f3d7275
Autor:
Mohansrinivas Chennakesavalu, Caileigh Pudela, Mark A. Applebaum, Sang Mee Lee, Yan Che, Arlene Naranjo, Julie R. Park, Samuel L. Volchenboum, Tara O. Henderson, Susan L. Cohn, Ami V. Desai
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100022- (2023)
Background: Racial/ethnic survival disparities in neuroblastoma were first reported more than a decade ago. We sought to investigate if these disparities have persisted with current era therapy. Methods: Two patient cohorts were identified in the Int
Externí odkaz:
https://doaj.org/article/0884887593ac4022bd8dab8a00e8d3e1
Autor:
Nicholas A. Vitanza, Rebecca Ronsley, Michelle Choe, Casey Henson, Mandy Breedt, Adriel Barrios-Anderson, Amy Wein, Christopher Brown, Adam Beebe, Ada Kong, Danielle Kirkey, Brittany M. Lee, Sarah E.S. Leary, Erin E. Crotty, Corrine Hoeppner, Susan Holtzclaw, Ashley L. Wilson, Joshua A. Gustafson, Jessica B. Foster, Jeffrey J. Iliff, Hannah E. Goldstein, Samuel R. Browd, Amy Lee, Jeffrey G. Ojemann, Navin Pinto, Juliane Gust, Rebecca A. Gardner, Michael C. Jensen, Jason S. Hauptman, Julie R. Park
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 36, Iss , Pp 100870- (2023)
Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population. Based on adoptive cellular therapy's clinical success against childhood leukemia and the preclinical efficacy against pediatric CNS tumors, chimeric
Externí odkaz:
https://doaj.org/article/0dd9cbf684b44b109bab4c85d507e99f
Autor:
Kelly C. Goldsmith, Julie R. Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi, Susan G. Groshen, Judith G. Villablanca, Kateryna Krytska, Lillian M. Lai, Patricia T. Acharya, Fariba Goodarzian, Bruce Pawel, Hiroyuki Shimada, Susan Ghazarian, Lisa States, Lynley Marshall, Louis Chesler, Meaghan Granger, Ami V. Desai, Rajen Mody, Daniel A. Morgenstern, Suzanne Shusterman, Margaret E. Macy, Navin Pinto, Gudrun Schleiermacher, Kieuhoa Vo, Holger C. Thurm, Joseph Chen, Marlon Liyanage, Gerson Peltz, Katherine K. Matthay, Esther R. Berko, John M. Maris, Araz Marachelian, Yael P. Mossé
Publikováno v:
Nature Medicine. 29:1092-1102
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in childre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05cb1069b5caae85576f8251b56aaa50
https://doi.org/10.1038/s41591-023-02297-5
https://doi.org/10.1038/s41591-023-02297-5
Autor:
Jasia Mahdi, Jorg Dietrich, Karin Straathof, Claire Roddie, Brian J. Scott, Tom Belle Davidson, Laura M. Prolo, Tracy T. Batchelor, Cynthia J. Campen, Kara L. Davis, Juliane Gust, Michael Lim, Robbie G. Majzner, Julie R. Park, Sonia Partap, Sneha Ramakrishna, Rebecca Richards, Liora Schultz, Nicholas A. Vitanza, Leo D. Wang, Crystal L. Mackall, Michelle Monje
Publikováno v:
Nature Medicine. 29:803-810
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::143fe1066eb3e5fc3eb3433c75c86c2f
https://doi.org/10.1038/s41591-023-02276-w
https://doi.org/10.1038/s41591-023-02276-w
Autor:
Kevin Campbell, Susan Groshen, Angela C. Evans, Stephen Wilson, Aimy Sebastian, Gabriela G. Loots, Araz Marachelian, Myriam Armant, Sharmistha Pal, Daphne A. Haas-Kogan, Julie R. Park, Meaghan Granger, Katherine K. Matthay, Matthew A. Coleman, Steven G. DuBois
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 115:1115-1128
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed9bb2e21be600a1d207d8917ee17e00
https://doi.org/10.1016/j.ijrobp.2022.11.045
https://doi.org/10.1016/j.ijrobp.2022.11.045
Autor:
Ami V. Desai, Andrew L. Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney, Mitchell Diccianni, Jacquelyn A. Hank, Marguerite T. Parisi, Barry L. Shulkin, Malcolm Smith, Jeffrey A. Moscow, Hiroyuki Shimada, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Paul M. Sondel, Julie R. Park, Alice L. Yu
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(35)
PURPOSEPostconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2 improved outcomes for patients with high-risk neuroblastoma enrolled on the randomized portion of Children's Oncology Gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8a59f18126714f9522dd294525fd001
https://pubmed.ncbi.nlm.nih.gov/35839426
https://pubmed.ncbi.nlm.nih.gov/35839426
Autor:
Navin Pinto, Arlene Naranjo, Xiangming Ding, Fan F. Zhang, Emily Hibbitts, Rebekah Kennedy, Rachelle Tibbetts, Shannon Wong-Michalak, David W. Craig, Zarko Manojlovic, Michael D. Hogarty, Susan Kreissman, Rochelle Bagatell, Meredith S. Irwin, Julie R. Park, Shahab Asgharzadeh
Publikováno v:
Clinical Cancer Research. 29:1546-1556
Purpose: Patients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neuroblastoma populations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53f32468b3310e19ffaff94139d79a9d
https://doi.org/10.1158/1078-0432.ccr-22-3032
https://doi.org/10.1158/1078-0432.ccr-22-3032
Autor:
Mahmoud M. Elzembely, Julie R. Park, Khaled F. Riad, Heba A. Sayed, Navin Pinto, Paul A. Carpenter, K. Scott Baker, Alaa El-Haddad
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-12 (2018)
Purpose: High-dose chemotherapy with autologous stem-cell rescue (SCR) is a key component of high-risk neuroblastoma (HRNB) therapy. Carboplatin, etoposide, and melphalan (CEM) or busulfan and melphalan (Bu/Mel) are the most evaluated, effective high
Externí odkaz:
https://doaj.org/article/13a25fdd0a97489385a4701535f8fb05